ASP Isotopes (NASDAQ:ASPI) Trading Down 5.3% on Insider Selling
by Doug Wharley · The Cerbat GemShares of ASP Isotopes Inc. (NASDAQ:ASPI – Get Free Report) fell 5.3% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $5.38 and last traded at $5.4050. 1,337,331 shares changed hands during trading, a decline of 70% from the average session volume of 4,482,298 shares. The stock had previously closed at $5.71.
Specifically, CFO Heather Kiessling sold 80,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $5.80, for a total value of $464,000.00. Following the completion of the transaction, the chief financial officer owned 732,500 shares of the company’s stock, valued at approximately $4,248,500. This trade represents a 9.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Analyst Upgrades and Downgrades
ASPI has been the topic of several recent research reports. Loop Capital set a $15.00 price target on ASP Isotopes in a report on Monday, October 27th. Canaccord Genuity Group restated a “buy” rating and set a $11.00 target price on shares of ASP Isotopes in a research note on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a report on Monday, December 22nd. Finally, Cantor Fitzgerald began coverage on shares of ASP Isotopes in a report on Thursday, December 4th. They set an “overweight” rating and a $13.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $13.00.
Read Our Latest Stock Report on ASPI
ASP Isotopes Price Performance
The stock has a market capitalization of $602.42 million, a price-to-earnings ratio of -4.17 and a beta of 3.42. The company has a current ratio of 6.14, a quick ratio of 6.10 and a debt-to-equity ratio of 1.04. The company’s 50 day moving average is $7.31 and its 200 day moving average is $8.51.
ASP Isotopes (NASDAQ:ASPI – Get Free Report) last released its quarterly earnings data on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.05). ASP Isotopes had a negative net margin of 1,259.12% and a negative return on equity of 190.44%. The company had revenue of $4.89 million during the quarter, compared to analyst estimates of $2.25 million. Research analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in ASPI. Quantbot Technologies LP purchased a new stake in ASP Isotopes in the third quarter valued at approximately $34,000. Ameritas Investment Partners Inc. raised its position in ASP Isotopes by 41.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock valued at $40,000 after purchasing an additional 1,600 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after purchasing an additional 2,548 shares during the period. Close Asset Management Ltd purchased a new position in ASP Isotopes during the 3rd quarter worth $72,000. Finally, Tower Research Capital LLC TRC increased its stake in ASP Isotopes by 96.7% in the second quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock valued at $80,000 after purchasing an additional 5,353 shares during the period. Institutional investors and hedge funds own 16.80% of the company’s stock.
ASP Isotopes Company Profile
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.